Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

'SIRT'ain Security: The Protein SIRT3 Protects The Heart
Sirtuin proteins have been shown to promote longevity in many organisms, and increased expression of one sirtuin protein, SIRT3, has been linked to increased human lifespan. New data, generated in mice, by Mahesh Gupta and colleagues, at the University of Chicago, Chicago, has revealed that Sirt3 helps protect the mouse heart.
generic viagra online
Physicians Wait For Health IT Guidelines, Officials Want 'Every Doctor's Office' Online
Physicians are still waiting for clear cut rules for how they must use health information technology in order to be eligible for economic stimulus-funded incentives, American Medical News, a publication of the American Medical Association, reports. The publication notes that (the $2 billion) "incentive money will directly address the use of EMRs, not the purchase of the systems." The sole, ambiguous requirement - that doctors must make "meaningful use" of the technology - will be defined by year"s end. But, industry consultants say doctors can and should get a head start on the governments expectation that they"ll be able to adopt the technology by 2011. Practices can expect requirements to include e-prescribing, certification through a government-approved certifying body, quality reporting, and the ability of one system to exchange information with others (Dolan, 6/15).
News of the day
Hyperion Therapeutics Receives Special Protocol Assessment Approval From FDA For Pivotal Phase III Trial In Urea Cycle Disorders
Hyperion Therapeutics announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the pivotal Phase III trial of investigational product HPN-100 (glycerol phenylbutyrate) in adults with urea cycle disorders (UCD). The SPA is a written agreement between the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of the Phase III trial to be used in support of a New Drug Application (NDA).
Endocrinology

Memory Test And PET Scans Detect Early Signs Of Alzheimer's

A large study of patients with mild cognitive impairment revealed that results from cognitive tests and brain scans can work as an early warning system for the subsequent development of Alzheimer"s disease. The research found that among 85 participants in the study with mild cognitive impairment, those with low scores on a memory recall test and low glucose metabolism in particular brain regions, as detected through positron emission tomography (PET), had a 15-fold greater risk of developing Alzheimer"s disease within two years, compared with the others in the study. The results, reported by researchers at the University of California, Berkeley, on Tuesday, July 14, at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease in Vienna, Austria, are a major step forward in the march toward earlier diagnoses of the debilitating disease. "Not all people with mild cognitive impairment go on to develop Alzheimer"s, so it would be extremely useful to be able to identify those who are at greater risk of converting using a clinical test or biological measurement," said the study"s lead author, Susan Landau, a post-doctoral fellow at UC Berkeley"s Helen Wills Neuroscience Institute and the Lawrence Berkeley National Laboratory. "The field, in general, is moving toward ways to select people during earlier stages of Alzheimer"s disease, including those who show no outward signs of cognitive impairment," said Dr. William Jagust, a faculty member of UC Berkeley"s Helen Wills Neuroscience Institute and principal investigator of the study. "By the time a patient is diagnosed with Alzheimer"s disease, there is usually little one can do to stop or reverse the decline. Researchers are trying to determine whether treating patients before severe symptoms appear will be more effective, and that requires better diagnostic tools than what is currently available." In the latest study, researchers compared a variety of measurements that had previously shown promise as early detectors of Alzheimer"s. The measurements included scores on the Auditory Verbal Learning Test; the volume of the hippocampus, the part of the brain associated with the formation of new memory; the presence of the apolipoprotein E4 gene, which has been linked to increased risk of Alzheimer"s; certain proteins found in the cerebrospinal fluid; and glucose metabolism detected in PET brain scans. A low rate of glucose metabolism in a particular brain region is considered a sign of poor neural function, most likely due to the loss of synapses in that area. "What"s really novel about our study is that we evaluated all of these biomarkers in the same subjects, so we could more easily compare the predictive value of any one measure over the others," said Landau. "The Auditory-Verbal Learning Test, which measures memory recall ability, and the PET scans measuring glucose metabolism were the two markers that clearly stood out over the others." The researchers pointed out that other measurements - in particular, hippocampus volume and the cerebrospinal fluid markers - also showed promise in predicting disease progression. However, when considering all the measurements together, PET scans and memory recall ability were the most consistent predictors. The researchers expect to have more complete information about which measures serve as the best predictors in a year as they continue to gather data for this ongoing study. An earlier study led by Jagust, a professor with joint appointments at UC Berkeley"s School of Public Health and the Lawrence Berkeley National Laboratory, found that PET scans and magnetic resonance imaging (MRI) could detect neurological changes in asymptomatic people who subsequently developed dementia or mental impairment, although it was too soon to say if those people would go on to develop Alzheimer"s. The research is part of the nationwide Alzheimer"s Disease Neuroimaging Initiative, a 60-center study funded by the National Institute on Aging. The ultimate goal of the initiative is to find a biomarker for Alzheimer"s that would predict individuals who will later develop Alzheimer"s disease. Ideally, this marker would be identifiable very early, even in individuals who do not yet show signs of mental impairment. Jagust heads the initiative"s research on PET imaging. The UC Berkeley study includes those patients who had measures for all biomarkers. Sarah Yang University of California - Berkeley


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009